- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04762160
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
March 21, 2024 updated by: Epizyme, Inc.
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a phase 2, multicenter, open-label study of oral tazemetostat in combination with rituximab in subjects with relapsed or refractory (R/R) follicular lymphoma (FL).
This study is designed to evaluate the safety and efficacy of tazemetostat in combination with rituximab in subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used, and used and features early futility stopping to maintain subject safety.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35223
- Alabama Oncology
-
-
California
-
Fountain Valley, California, United States, 92708
- Compassionate Cancer Care
-
-
Colorado
-
Boulder, Colorado, United States, 80303
- USOR/Rocky Mountain Cancer Centers
-
-
Illinois
-
Niles, Illinois, United States, 60714
- USOR/ Illinois Cancer Specialists
-
Rolling Meadows, Illinois, United States, 60008
- XCancer/ Northwest Oncology & Hematology
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48336
- Revive/Oakland Medical Group
-
Sterling Heights, Michigan, United States, 48314
- Revive/Hematology Oncology Associates of Rockland
-
-
New York
-
Albany, New York, United States, 12206
- USOR/ NY Oncology Hematology
-
-
North Carolina
-
Greenville, North Carolina, United States, 27858
- East Carolina University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
- USOR/ Oncology & Hematology Care Clinical Trials
-
Kettering, Ohio, United States, 45409
- XCancer/Dayton Physicians Network
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
- XCancer/Tennessee Cancer Specialists
-
-
Texas
-
Austin, Texas, United States, 78705
- USOR/ Texas Oncology
-
Dallas, Texas, United States, 75230
- USOR/Texas Oncology
-
San Antonio, Texas, United States, 78240
- USOR/ Texas Oncology
-
Tyler, Texas, United States, 75702
- USOR/ Texas Oncology
-
Weslaco, Texas, United States, 78596
- USOR/Texas Oncology
-
-
Virginia
-
Gainesville, Virginia, United States, 20155
- USOR/Virginia Cancer Specialists
-
Roanoke, Virginia, United States, 24014
- USOR/Oncology & Hematology Associates of Southwest Virginia
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men and women of 18 years of age and older
- Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol
- Eastern Cooperative Oncology Group (ECOG) score of 0 </=, 1 or 2
- Life expectancy (in the opinion of the investigator) of >3 months before enrollment
- Have histologically confirmed FL, Grade 1 to 3a. Subjects may have R/R disease following at least 2 standard prior systemic treatment regimens where at least 1 anti- CD20-based regimen was used
- Treatment recommended in accordance with the Groupe d'Etude des Lymphomes b Folliculaires (GELF) criteria
Meet the following laboratory parameters:
- Absolute neutrophil count (ANC) ≥ 750 cells/μL (0.75 x 109/L), or ≥ 500 cells/μL (0.50 x 109/L) in subjects with documented bone marrow involvement
- Platelet count ≥ 50,000 cells/μL (50 x 109/L), or ≥ 30,000 cells/μL (30 x 109/L) in subjects with documented bone marrow involvement, and without transfusion dependence
- Hemoglobin ≥ 8 g/dL
- Serum alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ≤ Incl3.0 x ULN, unless related to disease involvement
- Total bilirubin ≤ 1.5 x ULN, unless due to disease involvement, Gilbert's syndrome, or hemolytic anemia
- Estimated creatinine clearance (ie, estimated glomerular filtration rate [eGFR] using Cockcroft-Gault) ≥ 40 mL/min
- At least one bi-dimensionally measurable nodal lesion > 1.5 cm in its longest diameter by computed tomography (CT) scan or magnetic resonance imaging (MRI)
- Any clinically significant toxicity related to a prior anticancer treatment (ie, chemotherapy, immunotherapy, and/or radiotherapy), except for alopecia, either resolved to ≤ Grade 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 or is clinically stable and no longer clinically significant
- Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic hepatitis B virus (HBV) infection
- Negative test results for hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
- Females of childbearing potential (FCBP) must have a negative serum pregnancy test (beta-human chorionic gonadotropin [β-hCG] test with a minimum sensitivity of 25 mIU/mL or equivalent units of β-hCG) at screening and within 24 hours prior to the first dose of study drug.
- FCBP must either practice complete abstinence or agree to use a highly effective method of contraception beginning at least 28 days prior to the first dose of study drug, during study treatment (including during dose interruptions), for 6 months after tazemetostat discontinuation, and for 12 months after rituximab discontinuation. .
- Male subjects must have had a successful vasectomy (with medically confirmed azoospermia) OR must either practice complete abstinence or agree to use a latex or synthetic condom during sexual contact with a FCBP from the first dose of study drug, during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation.
Exclusion Criteria:
- Prior exposure to Tazemetostat or other inhibitor(s) of EZH2
- Grade 2b, mixed histology, or transformed FL
Treatment with any of the following anticancer therapies within the timeframe of a specific treatment prior to first dose of study drug:
- Cytotoxic chemotherapy within 21 days
- Noncytotoxic chemotherapy (e.g. small molecule inhibitor) within 14 days
- Nitrosoureas within 6 weeks
- Prior immunotherapy within 4 weeks
- Radiotherapy- within 6 weeks from prior radioisotope therapy; within 12 weeks from 50% pelvic or total body irradiation
- Any investigational treatment within 4 weeks or at least 5 half lives, whichever is shorter
- History of solid organ transplant
- Major surgery within 4 weeks of the start of study treatment
- Thrombocytopenia, neutropenia, or anemia of Grade > 3 (per CTCAE v5.0 criteria) or any prior history of myeloid malignancies, including MDS/AML or MPN
- Prior history of T-LBL/T-ALL
- Unwillingness to exclude grapefruit juice-containing products, Seville oranges, and grapefruits from the diet and/ or consumed within 1 week of the first dose of study drug
- Subjects taking medications that are known strong cytochrome P450 (CYP)3A inhibitors and strong or moderate CYP3A inducers (including St. John's wort)
- Any uncontrolled illness
- History of clinically significant cardiovascular abnormalities
- History of clinically significant gastrointestinal (GI) conditions
- Other diagnosis of cancer that is likely to require treatment in the next 2 years
- Females who are pregnant or lactating/breastfeeding
- Received a live virus vaccination within 28 days of first dose of rituximab
- Concurrent participation in a separate investigational therapeutic study
- Psychiatric illness/social situations that would interfere with study compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tazmetostat in combination with rituximab
Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1 (C1D1).
Tazemetostat will be administered from C1D1 to the end of Cycle 24, for 24 months of therapy or until disease progression, unacceptable toxicity, or withdrawal of consent.
Rituximab will be administered by either subcutaneous injection or IV infusion according to the regional product prescribing information, labeling and institutional guidelines.
Rituximab will be administered at a dose of 375 mg/m2 on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles.
|
Study Drug
Other Names:
Partner Drug
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Planned to be assessed during Cycles 3, 6, 12, 18, and 24.
|
ORR was defined as the percentage of participants with WT EZH2 status who achieved a complete response (CR) or partial response (PR) according to the 2014 Lugano Classification as assessed by investigator and blinded independent review committee (IRC).
CR = complete metabolic response per positron emission tomography-computed tomography (PET-CT) based response or complete radiologic response per CT-based response.
PR = partial metabolic response per PET-CT-based response or partial remission per CT-based response.
|
Planned to be assessed during Cycles 3, 6, 12, 18, and 24.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: Planned to be assessed from first dose of study drug to earliest date of disease progression or death as assessed up to 24 months by an IRC
|
PFS was defined as the time from first dose of study drug to the time of the earliest date of CR or PR per the 2014 Lugano Classification or death, whichever occurred first, as assessed by an IRC.
CR= complete metabolic response per PET-CT based response or complete radiologic response per CT-based response.
PR= partial metabolic response per PET-CT-based response or partial remission per CT-based response.
|
Planned to be assessed from first dose of study drug to earliest date of disease progression or death as assessed up to 24 months by an IRC
|
Duration of Response (DOR)
Time Frame: Planned to be assessed from earliest date of CR or PR to documented progression or death as assessed up to 24 months by an IRC
|
DOR was defined as the time from the earliest date of CR or PR per the 2014 Lugano Classification to documented progression or death, whichever comes first, as assessed by an IRC.
CR= complete metabolic response per PET-CT based response or complete radiologic response per CT-based response.
PR= partial metabolic response per PET-CT-based response or partial remission per CT-based response.
|
Planned to be assessed from earliest date of CR or PR to documented progression or death as assessed up to 24 months by an IRC
|
ORR in a Subset of Participants With MT EZH2
Time Frame: Planned to be assessed at the following timepoints: Cycles 3, 6, 12, 18, and 24
|
ORR was assessed according to 2014 Lugano Classification, in the pooled group regardless of mutation status and in a subset of participants with MT EZH2.
|
Planned to be assessed at the following timepoints: Cycles 3, 6, 12, 18, and 24
|
ORR in Rituximab Refractory Participants
Time Frame: Planned to be assessed at the following timepoints: Cycle 3, Cycle 6, Cycle 12, Cycle 18, and Cycle 24.
|
ORR was assessed according to 2014 Lugano Classification, in rituximab refractory participants.
|
Planned to be assessed at the following timepoints: Cycle 3, Cycle 6, Cycle 12, Cycle 18, and Cycle 24.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Ipsen Medical Director, Ipsen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2020
Primary Completion (Actual)
March 22, 2022
Study Completion (Actual)
March 22, 2022
Study Registration Dates
First Submitted
February 5, 2021
First Submitted That Met QC Criteria
February 16, 2021
First Posted (Actual)
February 21, 2021
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Follicular
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- EZH-1401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Epizyme, Inc.RecruitingFollicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular LymphomaUnited States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
Clinical Trials on Tazemetostat
-
Loma Linda UniversityWithdrawnCytokine Release Syndrome | COVID-19 Acute Respiratory Distress Syndrome
-
Hutchison Medipharma LimitedRecruitingRelapsed/Refractory Follicular Lymphoma With EZH2China
-
Eisai Co., Ltd.Recruiting
-
Prisma Health-UpstateIpsenRecruitingSolid Tumor | ARID1A Gene MutationUnited States
-
Epizyme, Inc.WEP ClinicalNo longer availableEpithelioid Sarcoma
-
Eisai Co., Ltd.CompletedRelapsed or Refractory B-cell Non-Hodgkin's LymphomaJapan
-
Eisai Co., Ltd.CompletedRelapsed or Refractory B-cell Non-Hodgkin's LymphomaJapan
-
Weill Medical College of Cornell UniversityEpizyme, Inc.; American Society of Clinical Oncology; Applebaum FoundationRecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell LymphomaUnited States
-
University of FloridaEpizyme, Inc.RecruitingPeripheral Nerve Sheath TumorUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupActive, not recruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditionsUnited States, Puerto Rico